Market Overview

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In FusionPharm, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit


The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the District of Colorado on behalf
of purchasers of FusionPharm, Inc. (OTC:FSPM) ("FusionPharm" or
the "Company") securities during the period between March 31, 2012 and
September 16, 2016, inclusive (the "Class Period"). Investors who wish
to become proactively involved in the litigation have until April 18,
2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must
apply to be appointed lead plaintiff and be selected by the Court. The
lead plaintiff will direct the litigation and participate in important
decisions including whether to accept a settlement for the Class in the
action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in FusionPharm securities
during the Class Period. Members of the Class will be represented by the
lead plaintiff and counsel chosen by the lead plaintiff. No class has
yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities
Exchange Act of 1934 by virtue of the defendants' failure to disclose
during the Class Period that the proceeds reported from stock sales as
revenue were proceeds of illegal sales.

According to the complaint, following a May 16, 2014 Order of Suspension
of Trading from the U.S. Securities and Exchange Commission for a lack
of accurate information concerning the Company's assets, revenues,
financial statements, business transactions, and financial condition,
the value of FusionPharm shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in
FusionPharm securities purchased on or after March 31, 2012 and held
through the revelation of negative information during and/or at the end
of the Class Period and would like to learn more about this lawsuit and
your ability to participate as a lead plaintiff, without cost or
obligation to you, please visit our website at
You may also request more information by contacting Brower Piven either
by email at
or by telephone at (410) 415-6616. Brower Piven also encourages
anyone with information regarding the Company's conduct during the
period in question to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s. If you choose to retain counsel,
you may retain Brower Piven without financial obligation or cost to you,
or you may retain other counsel of your choice. You need take no action
at this time to be a member of the class.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at